QURE
What one share of uniQure holds
Pharmaceutical Preparations
We are a leader in the field of gene therapy, seeking to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results.
uniQure’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-03-31; the balance sheet is as of 2026-03-31.
| Sales | $0.30 |
|---|---|
| Profit | −$3.49 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$2.88 |
| Cash and investments | $2.22 |
| Debt | $0.79 |
| Book value | $2.37 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.18 | −$3.11 | $0.14 | −$2.61 | — | $7.39 |
| 2020 | $0.84 | −$2.81 | $0.16 | −$3.20 | — | $5.45 |
| 2021 | $11.19 | $7.04 | $0.37 | $5.78 | — | $12.87 |
| 2022 | $2.28 | −$2.71 | $0.38 | −$3.48 | — | $10.13 |
| 2023 | $0.33 | −$6.47 | $0.15 | −$3.21 | — | $4.34 |
| 2024 | $0.56 | −$4.92 | $0.07 | −$3.83 | — | −$0.14 |
| 2025 | $0.28 | −$3.46 | $0.01 | −$3.10 | — | $3.19 |